When COVID-19 exploded around the world, in-progress neurodegenerative disease trials – as well as studies preparing to launch – were faced with a sudden and unexpected challenge: how to adapt their approach with the least disruption possible.

If your study is struggling to reinvent its tactics in the face of COVID-19, read this eBook to find out how to overcome challenges in:

  • Safety assessments
  • Staff training
  • Budget control
  • Patient risk management
  • and more

View PDF